JP2021522247A5 - - Google Patents

Info

Publication number
JP2021522247A5
JP2021522247A5 JP2020559442A JP2020559442A JP2021522247A5 JP 2021522247 A5 JP2021522247 A5 JP 2021522247A5 JP 2020559442 A JP2020559442 A JP 2020559442A JP 2020559442 A JP2020559442 A JP 2020559442A JP 2021522247 A5 JP2021522247 A5 JP 2021522247A5
Authority
JP
Japan
Prior art keywords
composition according
solvate
phenyl
pharmaceutical composition
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020559442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522247A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028551 external-priority patent/WO2019209738A1/en
Publication of JP2021522247A publication Critical patent/JP2021522247A/ja
Publication of JP2021522247A5 publication Critical patent/JP2021522247A5/ja
Pending legal-status Critical Current

Links

JP2020559442A 2018-04-24 2019-04-22 肝疾患における好中球エラスターゼ阻害薬の使用 Pending JP2021522247A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662074P 2018-04-24 2018-04-24
US62/662,074 2018-04-24
PCT/US2019/028551 WO2019209738A1 (en) 2018-04-24 2019-04-22 Use of neutrophil elastase inhibitors in liver disease

Publications (2)

Publication Number Publication Date
JP2021522247A JP2021522247A (ja) 2021-08-30
JP2021522247A5 true JP2021522247A5 (enExample) 2022-04-27

Family

ID=68236763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559442A Pending JP2021522247A (ja) 2018-04-24 2019-04-22 肝疾患における好中球エラスターゼ阻害薬の使用

Country Status (11)

Country Link
US (2) US10806735B2 (enExample)
EP (1) EP3784657A4 (enExample)
JP (1) JP2021522247A (enExample)
KR (1) KR20210002573A (enExample)
CN (1) CN113614070A (enExample)
AU (2) AU2019257632A1 (enExample)
CA (1) CA3101274A1 (enExample)
IL (1) IL278207A (enExample)
SG (1) SG11202010521VA (enExample)
TW (1) TW202011965A (enExample)
WO (1) WO2019209738A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CA3193057A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
EP4210705A4 (en) * 2020-09-11 2024-11-13 Terns Pharmaceuticals, Inc. SOLID DISPERSION FORMULATIONS OF A FXR AGONIST
CN114085173B (zh) * 2021-10-18 2024-04-16 嘉兴学院 一种2-硝基-4-甲砜基苯甲醛的制备方法
CN115976192A (zh) * 2022-12-02 2023-04-18 西安华壹健康医学检验实验室有限公司 一种用ne基因表达量检测评估脂肪肝的方法
CN117357508B (zh) * 2023-11-03 2024-05-17 中山大学孙逸仙纪念医院 西维来司他在制备治疗原发性胆汁性胆管炎的药物中的应用
CN119499379B (zh) * 2024-09-23 2025-09-05 广东医科大学 Elane基因作为心力衰竭靶点的制药用途和西维来司他的新用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903356B (zh) 2007-12-20 2013-05-22 拜耳知识产权有限责任公司 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
US9475779B2 (en) * 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
EP3777863A1 (en) * 2014-09-12 2021-02-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2016050835A2 (en) 2014-10-02 2016-04-07 Ruprecht-Karls-Universität Heidelberg Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
EA201791258A1 (ru) * 2015-01-09 2017-12-29 Джилид Аполло, Ллс Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
KR20170129191A (ko) 2015-03-18 2017-11-24 바이엘 파마 악티엔게젤샤프트 (4s)-4-[4-사이아노-2-(메틸설폰일)페닐]-3,6-다이메틸-2-옥소-1-[3-(트라이플루오로메틸)페닐]-1,2,3,4-테트라하이드로 피리미딘-5-카보나이트릴의 생성 방법
CR20170456A (es) * 2015-04-07 2018-06-13 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapias combinadas
KR20180074793A (ko) 2015-11-13 2018-07-03 바이엘 파마 악티엔게젤샤프트 만성 상처 치료를 위한 4-(4-시아노-2-티오아릴)다이하이드로피리미디논
GB201608453D0 (en) 2016-05-13 2016-06-29 Univ Liverpool Muscle regeneration
KR102399254B1 (ko) * 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물

Similar Documents

Publication Publication Date Title
JP2021522247A5 (enExample)
JP2023002662A5 (enExample)
CN104918613B (zh) 通过给予秋水仙碱衍生物治疗或预防心血管事件
JP5911929B2 (ja) 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
JP2015528471A5 (enExample)
US20240325356A1 (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
JP2023541430A5 (enExample)
JP2023541432A5 (enExample)
JP2020529995A5 (enExample)
JP2019515909A5 (enExample)
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
JP2024095711A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
JP2009511450A5 (enExample)
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
CN101939001A (zh) 用于治疗卵巢癌的含有紫杉醇的组合
JP2020500868A5 (enExample)
JP2005527575A5 (enExample)
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
JP2022517902A5 (enExample)
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
CN107072996A (zh) 血脂异常症治疗剂
JP2021521227A5 (enExample)
JP2009532494A5 (enExample)
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
FI3941466T3 (fi) Vafidemstat epävakaan persoonallisuushäiriön ei-aggressiivisen oireiden hoitoon